Treatment with BAY 2927088 led to durable responses in patients previously treated HER2-mutant NSCLC

Dermatologic adverse events in the treatment of NSCLC with amivantamab plus lazertinib significantly reduced

Consolidation durvalumab after cCRT shows decreased disease progression in LS-SCLC

Subcutaneous pembrolizumab is a viable treatment option for mNSCLC

Addition of radical prostatectomy to systemic treatment improves survival in oligometastatic prostate cancer

The added value of integrative medicine

Urine test could reduce post-op scans for kidney cancer by half

Micro-ultrasound is as effective as MRI in detecting prostate cancer

Bone-protective agents given with enzalutamide with or without radium-223 show greater survival benefits in mCRPC

Darolutamide plus ADT provides deep and durable PSA responses in metastatic hormone-sensitive prostate cancer

Transperineal biopsy improves prostate cancer detection

Adjuvant docetaxel shows no significant advantage compared to surveillance in high-risk prostate cancer after 10 years